Navigation Links
Genesis Biopharma Mentioned Favorably in BioMedReports Article
Date:5/22/2012

LOS ANGELES, May 22, 2012 /PRNewswire/ -- Genesis Biopharma, Inc. (OTC/BB: GNBP), a biotechnology company developing targeted cancer immunotherapies, was mentioned favorably in an article in BioMedReports that was issued earlier today. The article can be accessed at the following link:

http://www.biomedreports.com/2012052295011/darling-dendreon-continues-taking-huge-hits.html

About Genesis Biopharma, Inc.

Genesis Biopharma, Inc. is engaged in the development and commercialization of autologous cell therapies for the treatment of various cancers. The company's lead product candidate, Contego, is a ready-to-infuse autologous cell therapy that utilizes tumor infiltrating lymphocytes for the treatment of patients with Stage IV metastatic melanoma. Contego is based on a currently available physician-sponsored investigational therapy at the National Cancer Institute, MD Anderson Cancer Center and the H. Lee Moffitt Cancer & Research Institute for the treatment of Stage IV metastatic melanoma. 

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the proposed public offering and the intended use of proceeds from the offering. The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including market conditions, risks associated with the cash requirements of the company's business and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission, and represent the company's views only as of the date they are made and should not be relied upon as representing the company's views as of any subsequent date. The company does not assume any obligation to update any forward-looking statements.


'/>"/>
SOURCE Genesis Biopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Genesis Biopharma Issues Letter To Shareholders
2. Genesis Biopharma Announces Proposed Public Offering of Common Stock and Warrants
3. ValGenesis Suite 2.5 Certified by SAP as Powered by SAP NetWeaver®
4. Scott Brooks Joins Regenesis Biomedical as Chief Operating Officer
5. ThermoGenesis Announces Approval of AXP® by India Ministry of Health
6. ThermoGenesis Announces Acceptance of AXP® Submission by Regulatory Body in China
7. Genesis Biosciences Announces New Hire and Promotions on Operational and Scientific Staff
8. ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal 2011 on September 12, 2011
9. Genesis Biopharma Signs Cooperative Research and Development Agreement With the National Cancer Institute to Develop Cancer Immunotherapies
10. Genesis Biopharma Names Former Member of the Joint Chiefs of Staff General Merrill McPeak to Board of Directors
11. Genesis Biopharma Names David Voyticky to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/16/2017)... (PRWEB) , ... June 16, 2017 , ... CTNext ... Entrepreneur Innovation Awards (EIA), held at The LOFT at Chelsea Piers in Stamford. , ... ideas to a panel of judges for an opportunity to secure $10,000 awards to ...
(Date:6/15/2017)... ... 15, 2017 , ... Cybrexa Therapeutics, a start-up cancer therapeutics ... in the amount of $6 million. An investment vehicle affiliated with HighCape Partners, ... The Series B funding will enable Cybrexa to complete the build-out of its ...
(Date:6/15/2017)... ... June 15, 2017 , ... ... new medical device startup. Dan Parsley, angelMD’s SVP of Corporate Development, served as ... this angelMD syndicate is part of Saranas’ recently announced $4 million Series B ...
(Date:6/15/2017)... Oxford, Conn. (PRWEB) , ... June 15, 2017 ... ... worldwide, has published a new guide on how to assemble a lab workstation. ... easy-to-follow terminology. Workstation components include Adam’s Nimbus or Eclipse balance, AVT anti-vibration table, ...
Breaking Biology Technology:
(Date:4/13/2017)... UBM,s Advanced Design and Manufacturing event in ... and evolving technology through its 3D Printing and Smart ... the expo portion of the event and feature a ... on trending topics within 3D printing and smart manufacturing. ... will take place June 13-15, 2017 at the Jacob K. ...
(Date:4/11/2017)... N.Y. , April 11, 2017 ... fingerprints, but researchers at the New York University ... College of Engineering have found that partial similarities ... security systems used in mobile phones and other ... thought. The vulnerability lies in the ...
(Date:4/5/2017)... Today HYPR Corp. , leading innovator ... of the HYPR platform is officially FIDO® Certified ... architecture that empowers biometric authentication across Fortune 500 enterprises ... over 15 million users across the financial services industry, ... product suites and physical access represent a growing portion ...
Breaking Biology News(10 mins):